Story perspectives

Ohio State's RNA Micelles Show Promise Against Colorectal Cancer

2/6/2026

24 4

Summary

Story summary

Researchers at The Ohio State University developed RNA micelles to deliver gemcitabine and survivin-targeting siRNA to metastatic colorectal cancer tumors.
The micelles are designed to minimize immune reactions and toxicity compared with standard chemotherapy.
In mouse models, treatment with these RNA micelles nearly eradicated tumors in 26 days.
The study highlights RNA micelles as a potentially transformative cancer therapy that could improve patient outcomes with fewer side effects.

1 of 1

Story summary

Researchers at The Ohio State University developed RNA micelles to deliver gemcitabine and survivin-targeting siRNA to metastatic colorectal cancer tumors.
The micelles are designed to minimize immune reactions and toxicity compared with standard chemotherapy.
In mouse models, treatment with these RNA micelles nearly eradicated tumors in 26 days.
The study highlights RNA micelles as a potentially transformative cancer therapy that could improve patient outcomes with fewer side effects.